BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15668290)

  • 1. Calreticulin expression in neuroblastoma--a novel independent prognostic factor.
    Hsu WM; Hsieh FJ; Jeng YM; Kuo ML; Chen CN; Lai DM; Hsieh LJ; Wang BT; Tsao PN; Lee H; Lin MT; Lai HS; Chen WJ
    Ann Oncol; 2005 Feb; 16(2):314-21. PubMed ID: 15668290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma.
    Chang HH; Lee H; Hu MK; Tsao PN; Juan HF; Huang MC; Shih YY; Wang BJ; Jeng YM; Chang CL; Huang SF; Tsay YG; Hsieh FJ; Lin KH; Hsu WM; Liao YF
    Clin Cancer Res; 2010 Sep; 16(17):4411-20. PubMed ID: 20736329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GRP78 expression correlates with histologic differentiation and favorable prognosis in neuroblastic tumors.
    Hsu WM; Hsieh FJ; Jeng YM; Kuo ML; Tsao PN; Lee H; Lin MT; Lai HS; Chen CN; Lai DM; Chen WJ
    Int J Cancer; 2005 Mar; 113(6):920-7. PubMed ID: 15514946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of GRP75 as an independent favorable prognostic marker of neuroblastoma by a proteomics analysis.
    Hsu WM; Lee H; Juan HF; Shih YY; Wang BJ; Pan CY; Jeng YM; Chang HH; Lu MY; Lin KH; Lai HS; Chen WJ; Tsay YG; Liao YF; Hsieh FJ
    Clin Cancer Res; 2008 Oct; 14(19):6237-45. PubMed ID: 18829503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VEGF expression correlates with neuronal differentiation and predicts a favorable prognosis in patients with neuroblastoma.
    Weng WC; Lin KH; Wu PY; Ho YH; Liu YL; Wang BJ; Chen CC; Lin YC; Liao YF; Lee WT; Hsu WM; Lee H
    Sci Rep; 2017 Sep; 7(1):11212. PubMed ID: 28894229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calreticulin Regulates VEGF-A in Neuroblastoma Cells.
    Weng WC; Lin KH; Wu PY; Lu YC; Weng YC; Wang BJ; Liao YF; Hsu WM; Lee WT; Lee H
    Mol Neurobiol; 2015 Aug; 52(1):758-70. PubMed ID: 25288151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calreticulin regulates MYCN expression to control neuronal differentiation and stemness of neuroblastoma.
    Lee AC; Shih YY; Zhou F; Chao TC; Lee H; Liao YF; Hsu WM; Hong JH
    J Mol Med (Berl); 2019 Mar; 97(3):325-339. PubMed ID: 30612140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of urokinase plasminogen activator and its receptor in metastasis and invasion of neuroblastoma.
    Li P; Gao Y; Ji Z; Zhang X; Xu Q; Li G; Guo Z; Zheng B; Guo X
    J Pediatr Surg; 2004 Oct; 39(10):1512-9. PubMed ID: 15486896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of DDX39A as a Potential Biomarker for Unfavorable Neuroblastoma Using a Proteomic Approach.
    Otake K; Uchida K; Ide S; Kobayashi Y; Kobayashi I; Kusunoki M
    Pediatr Blood Cancer; 2016 Feb; 63(2):221-7. PubMed ID: 26469522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor II mRNA-binding protein 3 expression predicts unfavorable prognosis in patients with neuroblastoma.
    Chen ST; Jeng YM; Chang CC; Chang HH; Huang MC; Juan HF; Hsu CH; Lee H; Liao YF; Lee YL; Hsu WM; Lai HS
    Cancer Sci; 2011 Dec; 102(12):2191-8. PubMed ID: 21917080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic discrimination among neuroblastomas according to Ha-ras/trk A gene expression: a comparison of the profiles of neuroblastomas detected clinically and those detected through mass screening.
    Tanaka T; Sugimoto T; Sawada T
    Cancer; 1998 Oct; 83(8):1626-33. PubMed ID: 9781958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological diagnosis for neuroblastoma using the combination of highly sensitive analysis of prognostic factors.
    Tajiri T; Tanaka S; Higashi M; Kinoshita Y; Takahashi Y; Tatsuta K; Suita S
    J Pediatr Surg; 2006 Mar; 41(3):560-6. PubMed ID: 16516635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
    Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
    Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
    Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
    J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.
    Burgues O; Navarro S; Noguera R; Pellín A; Ruiz A; Castel V; Llombart-Bosch A
    Virchows Arch; 2006 Oct; 449(4):410-20. PubMed ID: 16941154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome.
    Raggi CC; Maggi M; Renzi D; Calabrò A; Bagnoni ML; Scaruffi P; Tonini GP; Pazzagli M; De Bernardi B; Bernini G; Serio M; Orlando C
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3866-73. PubMed ID: 11061551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.